SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Speech balloon conversation in puzzle shape vector illustration card. Human hands exchange information in retro 80s collage vector illustration. Concept of success in communication, support, cooperation; new projects, professional growth.
Immunology and inflammation
Pliant Brings in Outside Experts to Review IPF Study Pause
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended suspension of the idiopathic pulmonary fibrosis trial.
February 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Robert F. Kennedy Jr.
Policy
RFK Jr. Confirmed as HHS Secretary Despite Continued Controversy
Robert F. Kennedy Jr.—whose history of anti-vaccine rhetoric has had the healthcare and biopharma industries on edge—was confirmed as Health and Human Services Secretary in a Senate vote along party lines.
February 13, 2025
 · 
2 min read
 · 
Heather McKenzie
Illustration of employee being let go, falling out of chair
Layoffs
Encoded Cuts 29% of Workforce to Extend Cash Runway, Advance Pipeline
Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected to keep the biotech operational well into 2026.
February 13, 2025
 · 
1 min read
 · 
Angela Gabriel
Art collage, hand with coins on blue background. Concept of business and finance.
Obesity
Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments
Obesity drug developers Aardvark, Helicore and Metsera have all netted raises in the past two weeks.
February 13, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Sanofi's Distribution Center in Quebec, Canada
Vaccines
Sanofi Hit With $250M Impairment After Scrapping J&J-Partnered E. coli Vaccine
Without providing specific data, Sanofi on Thursday announced that the experimental vaccine did not significantly prevent invasive E. coli disease versus placebo.
February 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Business
Navigating Patient Journeys with Tom Whitehead
In this episode, presented by the Genscript Biotech Global Forum 2025, BioSpace’s Head of Insights Lori Ellis and Tom Whitehead continue to discuss the patient and caregiver experience, where Tom gives his insights to the future of CGTs.
February 13, 2025
 · 
1 min read
 · 
Lori Ellis
Female alcoholism concept. Unhappy woman sitting at bottle bottom hugging her knees. Sad drunk wife or alcoholic mother. Social issue, abuse, addiction. Empty alcohol drink bottles vector Illustration
GLP-1
Novo’s Semaglutide Shows Promise for Alcohol Use Disorder
The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for addictive disorders.
February 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Roche's tower in Shanghai, China
Approvals
Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy
Evrysdi is the first, and so far only, noninvasive disease-modifying treatment for spinal muscular atrophy.
February 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Signage at Pfizer's world headquarters in New York City
Approvals
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate cancer, while recent readouts also position the pharma as a strong contender in colorectal cancer and bladder cancer.
February 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS